Biperiden (lactate)

Biperiden (KL 373) lactate is an orally active non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors. Biperiden (KL 373) lactate inhibits acetylcholine and enhances dopamine signaling in the central nervous system. Biperiden (KL 373) lactate has the potential for the research of Parkinson's disease and other related psychiatric disorders^[1][2]. In Vitro: Biperiden lactate (29.6 μg/ml, 72 hours) can significantly induce apoptosis and inhibit proliferation at high doses in human pancreatic ductal adenocarcinoma cells^[1].
In Vivo: Biperiden lactate (intraperitoneal injection, 10 mg/kg, everyday, 3 weeks) reduces tumor size by 83% in subcutaneous xenograft mouse using Panc-1 human pancreatic ductal adenocarcinoma cells^[1].
Biperiden lactate (intraperitoneal injection, 8 mg/kg, every 8 hours, 10 days) can reduce frequency of spontaneous seizures and extracellular hippocampal glutamate levels while cause a long-term decrease in hippocampal excitability^[2].